AUSTIN, Texas, July 16, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Bryan Lawlis, Ph.D., to its Board of Directors, effective immediately.
“We are delighted to welcome Dr. Lawlis to our Board, Bryan is a seasoned biotechnology industry executive who brings a tremendous amount of manufacturing and process development expertise,” said Anthony G. Quinn, M.B Ch.B, Ph.D., interim chief executive officer of Aeglea. “Bryan’s operational and board experience includes time with both growth-stage and large-scale biotechnology companies, and we look forward to his input and guidance as we advance our clinical trials and pipeline.”
“This is an exciting time to be joining Aeglea as it moves forward with its lead development program, pegzilarginase, particularly in light of the recently announced clinically relevant treatment effects with respect to Arginase 1 Deficiency,” said Dr. Lawlis. “I look forward to working with the Board as the Company develops its research pipeline of enzyme-based therapeutics.”
Dr. Lawlis served as CEO of Itero LLC from 2011 to 2017 and from 2007 to 2011 was co-founder and CEO of Itero BioPharmaceuticals, Inc. Before that, he held roles of COO, president and CEO of Aradigm Corporation from 2001 to 2006. From 1996 to 2001, Dr. Lawlis co-founded Covance Biotechnology Services and held the positions of president, CEO and executive chairman. Dr. Lawlis worked at Genentech from 1981 to 1996 where he rose to the position of vice president of process science. Dr. Lawlis’s current board appointments include independent directorships at Biomarin Pharmaceutical, Geron Corporation, and Coherus Biosciences.
Dr. Lawlis has a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in biochemistry from Washington State University. Dr. Lawlis was a National Institutes of Health postdoctoral fellow at Kansas State University and holds 13 patents in the United States.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Safe Harbor / Forward Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our cash forecasts, the timing and success of our clinical trials and related data, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, success in our collaborations and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
investors@aegleabio.com
Media Contact:
David Calusdian
Sharon Merrill Associates
AGLE@investorrelations.com